Drug
Givinostat clinical trials
Also written ITF2357.
Includes 1 study of Givinostat hydrochloride.
- studies test it
- 25
- open now
- 4
- in phase 3
- 4
- first study started
- 2006
Keep track of what changes. Save the givinostat studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
- ITF2357
- 17
Studies by the year they started
25 studies that test it; most in 2007 (3)
| Year | Studies |
|---|---|
| 2006 | 2 |
| 2007 | 3 |
| 2008 | 3 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2013 | 3 |
| 2017 | 2 |
| 2018 | 1 |
| 2021 | 1 |
| 2022 | 3 |
| 2024 | 2 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 10
- Phase 2
- 16
- Phase 3
- 4
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 24 · Other 1
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses givinostat is read from its arms, and is right about nine times in ten.
Testing it · 25
- Efficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular DystrophyRecruitingPhase 3ItalfarmacoNCT05933057Written as Givinostat
- Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia VeraRecruitingPhase 3ItalfarmacoNCT06093672Written as Givinostat
- Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability StudyRecruitingPhase 2/3ItalfarmacoNCT03373968Written as Givinostat
- Pharmacokinetics and Safety of Givinostat in DMD Patients Ages From at Least 2 Years to Less Then 6 Years OldRecruitingPhase 2ItalfarmacoNCT06769633Written as Givinostat Hydrochloride
- Pharmacokinetics, Safety and Tolerability of ITF2357 in Participants With Chronic Hepatic Impairment and With Normal Hepatic FunctionCompletedPhase 1ItalfarmacoNCT06736223Written as ITF2357
- Long-term Study Evaluating the Effect of Givinostat in Patients With Chronic Myeloproliferative NeoplasmsActive, not recruitingPhase 2ItalfarmacoNCT01761968Written as givinostat
- Givinostat and Metabolites Pharmacokinetics in Urine and Plasma (Part 3)CompletedPhase 1ItalfarmacoNCT05860114Written as Givinostat
- Perpetrator DDI Potential of Givinostat as Inhibitor and Inducer of CYP3A and P-gp ActivityCompletedPhase 1ItalfarmacoNCT05492318Written as Givinostat 10 mg/mL
- Clinical Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Becker Muscular DystrophyCompletedPhase 2ItalfarmacoNCT03238235Written as Givinostat
- The Potential of Givinostat as DDI Victim in Co-administration P-gp Inhibitor (Part 2)CompletedPhase 1ItalfarmacoNCT05845567Written as Givinostat
- Placebo-Corrected Effects of Therapeutic Dose (100 mg) and Supratherapeutic Dose (300 mg) of ITF2357 (Givinostat) and Moxifloxacin on QT/QTC IntervalCompletedPhase 1ItalfarmacoNCT04821063Written as ITF2357 10 mg/mL
- A Study to Assess Safety/Tolerability, pk, Effects on Histology, Clinical Parameters of Givinostat in Children With DMDCompletedPhase 1/2ItalfarmacoNCT01761292Written as Givinostat
- Effect of ITF2357 on Mucosal Healing in Patients With Moderate-to-severe Active Crohn's DiseaseTerminatedPhase 1/2ItalfarmacoNCT00792740Written as ITF2357
- Clinical Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular DystrophyCompletedPhase 3ItalfarmacoNCT02851797Written as givinostat
- Phase II Clinical Trial of ITF2357 In Patients With Relapsed/Refractory Multiple MyelomaTerminatedPhase 2ItalfarmacoNCT00792506Written as ITF2357
- phII Study of an HDAC Inhibitor in Very High-risk Relapsed/Refractory Hodgkin's Lymphoma PatientsTerminatedPhase 1/2ItalfarmacoNCT00496431Written as histone deacetylase inhibitor (ITF2357)
- Phase II Study of Histone-deacetylase Inhibitor ITF2357 in Refractory/Relapsed Lymphocytic LeukemiaTerminatedPhase 2ItalfarmacoNCT00792831Written as ITF2357
- Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's LymphomaCompletedPhase 1/2ItalfarmacoNCT00792467Written as ITF2357
- Open Label, Multicentre Trial to Assess Safety and Efficacy of ITF2357 in Active Systemic Juvenile Idiopathic ArthritisCompletedPhase 2ItalfarmacoNCT00570661Written as ITF2357
- Open-Label Extension of the Dose Finding Study (DSC/08/2357/36) in Patients With Poly Juvenile Idiopathic ArthritisTerminatedNot applicableItalfarmacoNCT01557452Written as Givinostat
Codes
What other systems call givinostat · ClinicalTrials.gg INT015099
- MeSH (NLM) C575255givinostatOne source NLM
- UNII (FDA) 5P60F84FBHGIVINOSTATConfirmed FDA, NLM, Wikidata
- Wikidata Q426257givinostatConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C71716GivinostatOne source FDA
- DrugBank DB12645One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C575255 | givinostat | One source NLM |
| UNII (FDA) | 5P60F84FBH | GIVINOSTAT | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q426257 | givinostat | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C71716 | Givinostat | One source FDA |
| DrugBank | DB12645 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.